Evidence map›Paper›PMID 39189540›Full record

ArticleJournal of genetic counseling2025

Expanded carrier screening for inherited genetic disease using exome and genome sequencing.

N Belnap, K Ramsey, A Abraham, A Ryan, S Rangasamy, A Bonfitto, M Naymik, M Huentelman, S Strom, D Perry and 4 more

Abstract read
In one paragraph

Article in Journal of genetic counseling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

N BelnapTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.ORCID 0009-0003-8868-5891
K RamseyTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.
A AbrahamTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.
A RyanTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.
S RangasamyTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.
A BonfittoTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.
M NaymikTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.
M HuentelmanTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.
S StromIllumina Inc., San Diego, California, USA.
D PerryIllumina Inc., San Diego, California, USA.
A SubramaniamUniversity of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
W W GrodyUCLA School of Medicine, Los Angeles, California, USA.
S SzelingerExact Sciences Corp, Phoenix, Arizona, USA.
V NarayananTranslational Genomics Research Institute (TGen), Phoenix, Arizona, USA.

Funding

Flint Family Foundation
6 · The paper itself

Abstract

The goal of this study was to assess the feasibility of using exome (ES) and genome sequencing (GS) in guiding preconception genetic screening (PCGS) for couples who are planning to conceive by creating a workflow for identifying risk alleles for autosomal recessive (AR) and X-linked (XL) disorders without the constraints of a predetermined, targeted gene panel. There were several limitations and challenges related to reporting and the technical aspects of ES and GS, which are listed in the discussion. We selected 150 couples from a cohort of families (trios) enrolled in a research protocol where the goal was to define the genetic etiology of disease in an affected child. Pre-existing, de-identified parental sequencing data were analyzed to define variants that would place the couple at risk of having a child affected by an AR or XL disorder. We identified 17 families who would be selected for counseling about risk alleles. We noted that only 3 of these at-risk couples would be identified if we limited ourselves to the current ACMG-recommended expanded carrier screening gene panel. ES and GS successfully identified couples who are at risk of having a child with a rare AR or XL disorder that would have been missed by the current recommended guidelines. Current limitations of this approach include ethical concerns, difficulties in reporting results including variant calling due to the rare nature of some of the variants, determining which disorders to report, as well as technical difficulties in detecting certain variants such as repeat expansions.

Indexed as

ExomeExome SequencingGenetic Carrier ScreeningGenetic Diseases, InbornGenetic TestingFemaleHumansMalecarrier testingexome sequencinggenetic counselinggenome sequencingpreconception genetic screeningrare disease

Identifiers

PMID39189540
PMCPMC11953577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.